The Wegovy pill's fast launch had primed investors for the possibility of a blowout as Novo fights to regain market share from Lilly. Yet the result raised concerns about the company's longer-term competitiveness.
The Wegovy pill's fast launch had primed investors for the possibility of a blowout as Novo fights to regain market share from Lilly. Yet the result raised concerns about the company's longer-term competitiveness.
<iframe src="https://hindustansphere.com/embed/cluster/6b66fcb3b49ffddf4b2b5adf6797706ad38a3c2f" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novo Nordisk Underwhelms Investors With Soft Wegovy Pill Sales"></iframe>
